Response assessment in paediatric high-grade glioma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group
- PMID: 32502458
- DOI: 10.1016/S1470-2045(20)30173-X
Response assessment in paediatric high-grade glioma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group
Erratum in
-
Correction to Lancet Oncol 2020; 21: e317-29.Lancet Oncol. 2020 Aug;21(8):e372. doi: 10.1016/S1470-2045(20)30379-X. Lancet Oncol. 2020. PMID: 32758470 No abstract available.
Abstract
Response criteria for paediatric high-grade glioma vary historically and across different cooperative groups. The Response Assessment in Neuro-Oncology working group developed response criteria for adult high-grade glioma, but these were not created to meet the unique challenges in children with the disease. The Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group, consisting of an international panel of paediatric and adult neuro-oncologists, clinicians, radiologists, radiation oncologists, and neurosurgeons, was established to address issues and unique challenges in assessing response in children with CNS tumours. We established a subcommittee to develop response assessment criteria for paediatric high-grade glioma. Current practice and literature were reviewed to identify major challenges in assessing the response of paediatric high-grade gliomas to various treatments. For areas in which scientific investigation was scarce, consensus was reached through an iterative process. RAPNO response assessment recommendations include the use of MRI of the brain and the spine, assessment of clinical status, and the use of corticosteroids or antiangiogenics. Imaging standards for brain and spine are defined. Compared with the recommendations for the management of adult high-grade glioma, for paediatrics there is inclusion of diffusion-weighted imaging and a higher reliance on T2-weighted fluid-attenuated inversion recovery. Consensus recommendations and response definitions have been established and, similar to other RAPNO recommendations, prospective validation in clinical trials is warranted.
Copyright © 2020 Elsevier Ltd. All rights reserved.
Similar articles
-
Response assessment in paediatric low-grade glioma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group.Lancet Oncol. 2020 Jun;21(6):e305-e316. doi: 10.1016/S1470-2045(20)30064-4. Lancet Oncol. 2020. PMID: 32502457 Review.
-
Response assessment in diffuse intrinsic pontine glioma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group.Lancet Oncol. 2020 Jun;21(6):e330-e336. doi: 10.1016/S1470-2045(20)30166-2. Lancet Oncol. 2020. PMID: 32502459 Review.
-
Response assessment in paediatric intracranial ependymoma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group.Lancet Oncol. 2022 Aug;23(8):e393-e401. doi: 10.1016/S1470-2045(22)00222-4. Lancet Oncol. 2022. PMID: 35901835 Review.
-
Review of imaging recommendations from Response Assessment in Pediatric Neuro-Oncology (RAPNO).Pediatr Radiol. 2023 Dec;53(13):2723-2741. doi: 10.1007/s00247-023-05780-w. Epub 2023 Oct 21. Pediatr Radiol. 2023. PMID: 37864711 Review.
-
Response assessment in pediatric neurooncology (RAPNO) criteria revisited: a practical navigation guide for neuroradiologists.Neuroradiology. 2024 Dec;66(12):2117-2142. doi: 10.1007/s00234-024-03493-x. Epub 2024 Oct 24. Neuroradiology. 2024. PMID: 39446196 Review.
Cited by
-
Low-Dose Apatinib Improves the Prognosis of Patients with Recurrent High-Grade Gliomas.Evid Based Complement Alternat Med. 2022 Sep 5;2022:3181133. doi: 10.1155/2022/3181133. eCollection 2022. Evid Based Complement Alternat Med. 2022. Retraction in: Evid Based Complement Alternat Med. 2023 Jun 21;2023:9853753. doi: 10.1155/2023/9853753. PMID: 36106030 Free PMC article. Retracted.
-
Joint EANM/SIOPE/RAPNO practice guidelines/SNMMI procedure standards for imaging of paediatric gliomas using PET with radiolabelled amino acids and [18F]FDG: version 1.0.Eur J Nucl Med Mol Imaging. 2022 Sep;49(11):3852-3869. doi: 10.1007/s00259-022-05817-6. Epub 2022 May 10. Eur J Nucl Med Mol Imaging. 2022. PMID: 35536420 Free PMC article.
-
Evaluation of the reporting quality of clinical practice guidelines on gliomas using the RIGHT checklist.Ann Transl Med. 2021 Jun;9(12):1002. doi: 10.21037/atm-21-2604. Ann Transl Med. 2021. PMID: 34277802 Free PMC article.
-
Comparison of intraoperative and post-operative 3-T MRI performed at 24-72 h following brain tumour resection in children.Neuroradiology. 2021 Aug;63(8):1367-1376. doi: 10.1007/s00234-021-02671-5. Epub 2021 Feb 25. Neuroradiology. 2021. PMID: 33629130
-
World Cancer Day 2021 - Perspectives in Pediatric and Adult Neuro-Oncology.Front Oncol. 2021 May 10;11:659800. doi: 10.3389/fonc.2021.659800. eCollection 2021. Front Oncol. 2021. PMID: 34041027 Free PMC article.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources